Page 142 - Big Data Analytics for Intelligent Healthcare Management

5.8 RESULTS, INTERPRETATION AND DISCUSSION 135

Period
140 136.17 min Techniques, period
Subject: 26 EMGa, BaseLine
EMGa, 1 month
128.17 min 115.93 min
120 Subject: 27 Subject: 27 EMGa, 3 months
EMGa, 6 months
EMGa, 12 months
100 91.13 min GSRa, BaseLine
100.60 min 89.01 min Subject: 25 Subject: 25 GSRa, 1 month
85.81 min
Subject: 26
Duration/frequency 80 Subject: 24 Subject: 23 Subject: 21 GSRa, 6 months
GSRa, 3 months
74.33 min
Subject: 23
GSRa, 12 months
72.63 min
73.40 min
60
40
20
0
BaseLine 1 month 3 months 6 months 12 months
FIG. 5.26
Analysis of TTH duration per frequency with time.

EMGav: The EMGav therapy also recorded a continuous reduction and improvement. In the first
month, a steep reduction was observed from 128.17 to 100.6min/week with an improvement result of
27.57min/week.
The overall improvement was 72.33min/week with a total improvement of 55.84min/week.
The dropout was 4.
The overall trend analysis showed that GSRav therapy was better than EMGav with 12.56% im-
provement but it was a slow performer in terms of subject dropouts, which showed that the subjects
had more trust, confidence, and interest in EMGav. Also, the rate of reduction and steepness for TTH
duration per frequency was better with a continuous improvement in the subjects.
The tableau plot for the EMGav and GSRav groups showed the analysis of variation of frequency
along with duration in the 12months time period (Fig. 5.27).
GSRav: The graph showed that the therapy worked well from the start to 3months and continuous
improvement in the reduction of frequency per duration in chronic TTH on the subjects was reflected.
But between 3 and 6months, the improvement was deeply hampered and the rate of reduction reversed
toward an increase in frequency per duration. It showed the fluctuation in the therapy process. After 6–
12months, again the therapy exhibited a steep reduction. The overall improvement in the 12months
period was recorded as 5.423 to 2.714 as 2.709 with a total dropout of 5. The fluctuation for 3months
showed the disinterest and distrust of the therapy among the subjects, which caused the dropouts.
EMGav: The EMGav therapy exhibited a continuous improvement in the reduction of chronic
TTH headaches in the experiment period. A steep reduction was recorded between 3 and 6months
and a continuous but gradual improvement in frequency per duration was the result over the experiment
duration. A complete improvement was recorded as 7.074 to 2.913 total as 4.161, which is almost dou-
ble that of GSRav with 4 dropouts due to various human reasons in the experiment period. This showed
an almost 180% improvement by the EMGav therapy over the GSRav therapy.